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UV radiation causes immunosuppression by depleting Langer-
hans cells, the major antigen-presenting cells in the epidermis.
In addition, there is an in£ux of CD11bþ macrophages which
release the immunosuppressive cytokine interleukin-10 into the
UV-exposed skin area. On the other hand, monocytes/macro-
phages have the potential to di¡erentiate into CD11cþ dendritic
cells which are capable of presenting antigens. Kevin Cooper and
coworkers (p. 802) observed that although monocytic cell migra-
tion peaked at day 1^3 after UV exposure, dermal CD1cþ den-
dritic cells underwent a rapid and prolonged depletion, which
did not recover until day 7.The same authors observed previously
that C3 and its bioactive product iC3b are critical for UV-in-
duced immunosuppression. Since iC3b binds to CD11b the
authors hypothesized that iC3b may be responsible for the delay
in di¡erentiation of monocytic cells which migrate into UV-ex-
posed skin, into dendritic cells. The key experiment of this paper
demonstrates that puri¢ed monocytes from human blood devel-
oped into dendritic cells in the presence of granulocyte macro-
phage colony stimulating factor. Addition of iC3b, however,
inhibits this di¡erentiation. This study nicely demonstrates that
UV radiation does not only deplete the skin from dendritic cells
which are potent antigen-presenting cells but also arrests mono-
cytic skin in¢ltrating cells from undergoing di¡erentiation into
dendritic cells via iC3b. The fact that UV radiation wipes out
antigen-presenting cells and in addition inhibits the recovery of
these cells explains the potent immunosuppressive capacity of
UV radiation.
DIGGING TO THE BASIS OF WRINKLES
One of the hallmark features of chronic solar/UV exposure
is photoaging, the primary feature of which is the formation
of wrinkles. The basis of UV-induced photoaging is the degrada-
tion of collagen by increased expression of matrix metalloprotei-
nases (MMP) including collagenase. Both UVA and UVB
have been demonstrated to induce MMPs. The group by John
Voorhees and Gary Fisher has previously shown that UV-induced
activation of MMPs is mediated via signal transduction through
activation of MAP kinases (ERK, JNK, and p38).These signaling
pathways activate the transcription factor AP-1 which ultimately
induces MMP expression. Generation of reactive oxygen species
by UV is believed to be involved in triggering MAP kinases.
Whether UV-radiation induces reactive oxygen species in vivo in
human skin, however, still remains a matter of debate. Taking
skin samples from volunteers exposed to 2 MED UV radiation,
Kang and coworkers show in this issue (p. 835) that UV indeed
induces hydrogen peroxide in human skin in vivo. Genistein is a
well-known potent inhibitor of tyrosine kinase activity. In addi-
tion, genistein was recently found to exert antioxidant properties.
Therefore, the authors postulated that genistein might be a suita-
ble substance to block UV-induced activation of MMPs. Indeed
they can show that genistein inhibits UV-induced activation of
ERK and JNK. They also studied the e¡ect of N-acetyl cysteine
(NAC), which is converted into the endogenous antioxidant glu-
tathione. Topical application of NAC inhibited ERK but not
JNK activation. Topical application of both NAC and genistein
blocked UV-induced AP-1 activation and consequently the in-
duction of collagenase. Based on these ¢ndings, the authors con-
clude that compounds like genistein or NAC which possess
tyrosine kinase inhibitory and/or antioxidant activities may pre-
vent photoaging.
Both compounds do not ¢lter UV since they did not inhibit
UV-induced erythema. This appears to be important since these
substances, though possibly preventing photoaging, would not
inhibit sunburn and therefore drive the sun worshippers out of
the sun on time. Nevertheless, it remains to be determined
whether substances like genistein which acts as a general tyrosine
kinase inhibitor and interferes with many other biological e¡ects
will be suitable for topical application in general practice. There-
fore, the digging continues.
KILLING SOFTLY ^ DEFENSE BY CLEAVAGE
One of the most striking discoveries in cutaneous biology in the
last years was the observation that the epidermis, in particular
keratinocytes, exhibits the capacity to secrete antimicrobial pep-
tides. One member of this family is the cathelicidins, a class of
small cationic peptide antibiotics. Human cathelicidin consists of
a conserved prosequence called the cathelin-like domain and a
C-terminal peptide named LL-37. To date, the antimicrobial ac-
tivity was attributed to LL-37. Accordingly, Richard Gallo’s
group has shown that mice in which CRAMP, the murine
equivalent of LL-37, has been knocked out are more susceptible
to cutaneous infection with streptococci. Whether the cathelin-
like domain of the cathelicidin proform exerts any biological ac-
tivity remained unclear so far. In this issue (p. 810), Zaiou and
coworkers shed light on this issue. Looking at the protein se-
quence of the cathelin-like protein they realized homology with
cysteine protease inhibitors. Therefore, they checked whether the
cathelin-like protein acts as a protease inhibitor. Indeed, they ob-
served that the cathelin-like protein e¡ectively inhibits the activ-
ity of the protease cathepsin L. Since proteases may cause severe
tissue damage, the cathelin-like protein may limit tissue damage.
Even more surprising was the observation that the cathelin-
like protein also exerts antimicrobial activity. This protein killed
a variety of human pathogens including E. coli and even methicil-
line-resistant stapholycoccus aureus (MRSA). Hence, in terms of
antimicrobial activity the cathelin-like protein seems to be even
more e¡ective than LL-37 since it also kills bacteria resistant to
LL-37. These ¢ndings may have important implications for the
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understanding of the innate immune response within the epider-
mis. Cathelicidin is produced as an inactive precursor that is pro-
teolytically cleaved inside activated neutrophils and at epithelial
sites of in£ammation. After cleavage both cleavage products,
LL-37 and the cathelin-like protein, exert potent antimicrobial
activities that complement each other. In addition, the cathelin-
like protein exerts inhibitory e¡ects on proteases. Through this
activity it may mitigate tissue injury since many deleterious ef-
fects during in£ammatory responses are attributed to the activity
of cathepsin L and other proteinases released from lysosomes dur-
ing in£ammatory responses. Antimicrobial host defenses are
usually associated with tissue destruction. Hence, by killing mi-
crobes but also by protecting the tissue via its antiprotease activ-
ity the cathelin-like protein may represent an antimicrobial
peptide following the theme ‘‘killing softly’’.
AN APPEALTO JOURNAL EDITORS BY EDEN
In this issue (p. 738), the European Dermatology^Epidemiology
Network (EDEN) challenges the psoriasis research community
and the Editors of Dermatology journals. The EDEN group per-
formed a retrospective survey of published randomized clinical
psoriasis trials. In particular, they evaluated the range of treatment
comparisons, the study designs and the quality of reporting.They
found 249 studies published in 226 papers in 13 journals. 56% of
the studies employed a parallel control group design, 43%
adopted a self-control design and only 1.2% a cross-over design.
The median number of patients recruited per study was 40 with a
range from 6 to 699. A total of 55 di¡erent treatment modalities
was assessed in these studies. Only 12.5% were comparative stu-
dies of treatment modalities in di¡erent therapeutic classes. The
median study duration was 7 weeks with a range from 1 to 104
weeks. Only 7% of all studies lasted more than 4 months.
Forty-four di¡erent score systems were employed to measure the
outcome.
Based on these and many other data collected within this
study, the EDEN group attributes a poor quality and a limited
clinical usefulness to the vast majority of studies. However, the
EDEN group not only criticize but also de¢nes the demands for
the future:
1 Placebo use should be restricted to the early phase of develop-
ment of new treatments. Subsequently comparative studies
with other established treatments are needed.
2 Long-term studies conducted under conditions close to clinical
practice are needed.
3 Duration of remission is clinically more relevant than the im-
provement of a clinical score, e.g., PASI.
4 Drop-outs re£ect dissatisfaction with treatment and therefore
merit special attention during the evaluation.
The EDEN group pleads that these four most important
recommendations should be considered by researchers and Edi-
tors when they design and plan to publish psoriasis trials in the
future.
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